On ATL1103
"The process of engagement with pharmaceutical partners naturally takes time, however Destum and ANP are aiming to complete this process to attract a suitable partner and progress into the definitive agreement stage
within the next three to six months, although it should be noted that any current partnering interaction
can lead to a formal offer from a party at any point in time from now."
On ATL1102
"ANP is currently investigating provision of ATL1102 under an Early Access Program (EAP) on
compassionate use or on a named patient basis in markets where the drug would qualify for use on
these grounds including those where the Company can charge for drug access resulting in a possible
early income stream. "
"ANP is in discussions with an experienced European based group to set up and run the program in
Europe for ANP. Pricing for such EAP access for patients to use ATL1102 would be determined with
the insight of the European firm, however as a point of reference the hospital price of TysabriTM in
Europe ranges from A$25-$33,000 per patient per annum. ANP expects to update the market on the
progress of this use of ATL1102 in the coming months as key components are confirmed."
